Bio-Rad Laboratories competitors

Mike McMullen is Agilent’s CEO-elect. He will assume the CEO position in March 2015 when William (Bill) Sullivan takes an advisory role until his retirement. As a first step in the CEO transition, McMullen has been named president and chief operating officer. McMullen has more than 30 years of industry experience and senior management experience at Agilent. He has been president of the company’s Chemical Analysis Group (CAG) since 2009, a role he still fills on an acting basis. As head of CAG, McMullen transformed the business, consistently delivering market-leading growth and profits. He championed strategic acquisitions and architected Agilent’s China strategy. He built the Agilent-wide Services business that has now been made one of Agilent’s three major businesses. McMullen has extensive experience working across Agilent’s businesses, and is recognized for his inspirational leadership style. He also has significant international experience, having lived in Japan, leading Agilent’s Japan field sales and support operations, and later adding responsibility for China field operations. McMullen joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst. He holds a bachelor's degree in economics and business administration from the University of Delaware and an MBA from Wharton Business School.

Francis Aurelio deSouza (born December 2, 1970) is an American entrepreneur and business executive. He is the president and chief executive officer (CEO) of Illumina and a member of the Board of Directors of The Walt Disney Company.

Gary Guthart joined Intuitive Surgical in April 1996. Effective January 2010, Guthart was appointed as Chief Executive Officer. In July 2007, he was promoted to President. Prior to that, in February 2006, Guthart assumed the role of Chief Operating Officer. Prior to joining Intuitive, Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Guthart is currently a member of the Board of Directors of Affymetrix, Inc. He received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology.

With a proven track record of bringing game-changing technologies to the market, Mr. Shamir joined Luminex Corporation as President, Chief Executive Officer, and Board Member in 2014. From 2006 to 2014, Mr. Shamir served as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Exalenz Bioscience Ltd. (TASE: EXEN). He has previously served as a Board Member at Scitex Corporation, Cogentix Medical (NASDAQ: CGNT), recently acquired by Laborie Medical Technologies, and invendo medical GmBH, now part of Ambu. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive - ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare. Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies.Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.Geoff is a member of the Business Roundtable, and the World Economic Forum’s International Business Council. He also co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group.An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He also serves as Medtronic’s Executive Sponsor to FIRST Robotics.Geoff received a bachelor’s degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame.